Please assess the completion status of the following clinical trial:

Trial Title: In-Vivo Activated T-Cell Depletion to Prevent GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute myelogenous leukemia, Acute lymphocytic leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Mantle cell, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis with disease-specific eligibility requirements as outlined in the protocol~* Donor Requirement: Must have a fully HLA-matched (10 of 10) related or unrelated donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization and apheresis.~Exclusion Criteria:~* Active CNS disease (the presence of leukemic blasts in the CSF)~* Pregnancy or breast-feeding~* SGOT \>3x upper limit of normal~* Creatinine \>2 or creatinine clearance \<50cc/hr.~* Fractional shortening by echocardiogram not within normal limits per institution~* Pulmonary function: DLCO less that 50% of normal predicted, corrected for anemia~* Prior allogeneic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).